Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

Abstract Background Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential sid...

Full description

Bibliographic Details
Main Authors: Dennis C. Sgroi, Kai Treuner, Yi Zhang, Tammy Piper, Ranelle Salunga, Ikhlaaq Ahmed, Lucy Doos, Sarah Thornber, Karen J. Taylor, Elena Brachtel, Sarah Pirrie, Catherine A. Schnabel, Daniel Rea, John M. S. Bartlett
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Breast Cancer Research
Subjects:
Breast Cancer Index
BCI (H/I)
Breast cancer
Predictive biomarker
Extended endocrine therapy
Online Access:https://doi.org/10.1186/s13058-022-01589-x

Internet

https://doi.org/10.1186/s13058-022-01589-x

Similar Items